Log in

Esperion Therapeutics News Headlines (NASDAQ:ESPR)

$68.35
-2.19 (-3.10 %)
(As of 02/21/2020 02:31 AM ET)
Today's Range
$66.31
Now: $68.35
$71.19
50-Day Range
$49.10
MA: $59.95
$73.84
52-Week Range
$33.13
Now: $68.35
$76.98
Volume940,400 shs
Average Volume651,941 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Headlines

Esperion Therapeutics (NASDAQ ESPR) News Headlines

Source:
DateHeadline
Esperions Multiple Positives, And Other News: The Good, Bad And Ugly Of BiopharmaEsperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - February 20 at 9:19 AM
BTIG Research Raises Esperion Therapeutics (NASDAQ:ESPR) Price Target to $90.00BTIG Research Raises Esperion Therapeutics (NASDAQ:ESPR) Price Target to $90.00
www.americanbankingnews.com - February 19 at 8:58 AM
 Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Post Quarterly Sales of $970,000.00 Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Post Quarterly Sales of $970,000.00
www.americanbankingnews.com - February 17 at 2:06 AM
Esperion Therapeutics Inc (NASDAQ:ESPR) Given Consensus Recommendation of "Hold" by BrokeragesEsperion Therapeutics Inc (NASDAQ:ESPR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 16 at 12:27 PM
 Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Announce Earnings of -$2.71 Per Share Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Announce Earnings of -$2.71 Per Share
www.americanbankingnews.com - February 15 at 6:14 PM
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Neutral at CitigroupEsperion Therapeutics (NASDAQ:ESPR) Downgraded to Neutral at Citigroup
www.americanbankingnews.com - February 14 at 12:51 PM
Noteworthy Friday Option Activity: ESPR, YUMC, VSATNoteworthy Friday Option Activity: ESPR, YUMC, VSAT
www.nasdaq.com - February 7 at 7:51 PM
Chardan Capital Reaffirms Hold Rating for Esperion Therapeutics (NASDAQ:ESPR)Chardan Capital Reaffirms Hold Rating for Esperion Therapeutics (NASDAQ:ESPR)
www.americanbankingnews.com - February 1 at 6:31 AM
Esperion: Recent Pullback Offers Buying Opportunity Ahead Of February PDUFA DatesEsperion: Recent Pullback Offers Buying Opportunity Ahead Of February PDUFA Dates
seekingalpha.com - January 31 at 6:17 PM
European Advisory Group Backs Esperions Cholesterol DrugsEuropean Advisory Group Backs Esperion's Cholesterol Drugs
www.fool.com - January 31 at 1:10 PM
European advisory group back Esperions bempedoic acidEuropean advisory group back Esperion's bempedoic acid
seekingalpha.com - January 31 at 8:09 AM
Esperion Announces Positive CHMP Opinion for the...Esperion Announces Positive CHMP Opinion for the...
www.benzinga.com - January 31 at 8:09 AM
European advisory group backs Esperion combo tablet for high cholesterolEuropean advisory group backs Esperion combo tablet for high cholesterol
seekingalpha.com - January 31 at 8:09 AM
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed DyslipidemiaEsperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
finance.yahoo.com - January 31 at 8:09 AM
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed DyslipidemiaEsperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
finance.yahoo.com - January 31 at 8:09 AM
One Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share PriceOne Thing To Remember About The Esperion Therapeutics, Inc. (NASDAQ:ESPR) Share Price
finance.yahoo.com - January 27 at 5:42 PM
Target N. V. Biotech Purchases 20,000 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) StockTarget N. V. Biotech Purchases 20,000 Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) Stock
www.americanbankingnews.com - January 27 at 3:46 PM
Esperion to Present at the 38th Annual J.P. Morgan Healthcare ConferenceEsperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 5:44 PM
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - January 3 at 4:50 PM
Esperion (ESPR) Almost Doubled In 2019, What Awaits The Stock In 2020?Esperion (ESPR) Almost Doubled In 2019, What Awaits The Stock In 2020?
www.nasdaq.com - January 3 at 6:16 AM
4 Healthcare Stocks With FDA Approvals on the Horizon4 Healthcare Stocks With FDA Approvals on the Horizon
www.fool.com - December 12 at 12:25 PM
Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ?Did Hedge Funds Drop The Ball On Esperion Therapeutics (ESPR) ?
finance.yahoo.com - December 12 at 12:25 PM
Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 6 at 3:02 PM
Can Cannabis 2.0 Kickstart Marijuana Stocks?Can Cannabis 2.0 Kickstart Marijuana Stocks?
www.fool.com - December 6 at 10:01 AM
Esperions Promising Drugs Under Review, Funds a ConcernEsperion's Promising Drugs Under Review, Funds a Concern
finance.yahoo.com - November 28 at 12:38 PM
Notable Monday Option Activity: ESPR, DY, SPOTNotable Monday Option Activity: ESPR, DY, SPOT
www.nasdaq.com - November 18 at 5:53 PM
Esperion Therapeutics Breaks Above 200-Day Moving Average - Bullish for ESPREsperion Therapeutics Breaks Above 200-Day Moving Average - Bullish for ESPR
www.nasdaq.com - November 18 at 12:53 PM
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific SessionsEsperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
finance.yahoo.com - November 17 at 7:25 PM
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 ResultsEsperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
finance.yahoo.com - November 12 at 2:56 PM
President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR)President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. (NASDAQ:ESPR)
finance.yahoo.com - November 10 at 8:48 AM
Is Esperion Therapeuticss (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?
finance.yahoo.com - November 9 at 1:11 PM
Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?Is Esperion Therapeutics's (NASDAQ:ESPR) Share Price Gain Of 215% Well Earned?
finance.yahoo.com - November 9 at 1:11 PM
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue EstimatesEsperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 6 at 2:56 PM
Esperion Therapeutics EPS misses by $0.57, misses on revenueEsperion Therapeutics EPS misses by $0.57, misses on revenue
seekingalpha.com - November 6 at 7:59 AM
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial ResultsEsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
finance.yahoo.com - November 6 at 7:59 AM
Esperion Therapeutics Q3 2019 Earnings PreviewEsperion Therapeutics Q3 2019 Earnings Preview
seekingalpha.com - November 5 at 7:05 PM
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific SessionsEsperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
finance.yahoo.com - November 4 at 7:52 AM
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
finance.yahoo.com - October 29 at 8:26 AM
Should You Buy Esperion Therapeutics, Inc. (ESPR)?Should You Buy Esperion Therapeutics, Inc. (ESPR)?
finance.yahoo.com - October 28 at 6:24 PM
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 ListBempedoic Acid Included in Top 10 Medical Innovations for 2020 List
finance.yahoo.com - October 25 at 1:48 PM
Heres Why Were Not At All Concerned With Esperion Therapeuticss (NASDAQ:ESPR) Cash Burn SituationHere's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
finance.yahoo.com - October 5 at 12:35 AM
Esperion Therapeutics: Low Risk And Primed For Substantial GrowthEsperion Therapeutics: Low Risk And Primed For Substantial Growth
seekingalpha.com - October 4 at 2:34 PM
Here's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn SituationHere's Why We're Not At All Concerned With Esperion Therapeutics's (NASDAQ:ESPR) Cash Burn Situation
finance.yahoo.com - October 4 at 2:34 PM
Monday 9/9 Insider Buying Report: ACHC, ESPRMonday 9/9 Insider Buying Report: ACHC, ESPR
www.marketwatch.com - September 10 at 5:54 AM
Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of SharesEsperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $259,125 of Shares
finance.yahoo.com - September 7 at 2:38 PM
Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - September 7 at 2:38 PM
Esperions Bempedoic Acid Succeeds in Phase II Diabetes StudyEsperion's Bempedoic Acid Succeeds in Phase II Diabetes Study
finance.yahoo.com - August 30 at 8:02 PM
Esperions bempedoic acid successful in mid-stage study in type 2 diabetics with high cholesterolEsperion's bempedoic acid successful in mid-stage study in type 2 diabetics with high cholesterol
seekingalpha.com - August 29 at 11:45 AM
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 DiabetesEsperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
finance.yahoo.com - August 29 at 11:45 AM
Esperions Drugs in Review Hold Potential, Funds a ConcernEsperion's Drugs in Review Hold Potential, Funds a Concern
www.nasdaq.com - August 27 at 9:09 AM
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel